Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

ValueAct Capital Increases Stake In Twenty-First Century Fox Inc (FOX)

Jeff Ubben’s ValueAct Capital increased its stake in Twenty-First Century Fox Inc (NASDAQ:FOX). In a newly amended filing with the Securities and Exchange Commission, ValueAct disclosed an activist position of 43.55 million class B shares, up from 31.39 million mentioned in the fund’s latest 13F filing. Following the increase, the stake amasses 5.5% of Twenty-First Century Fox’s class B stock.


ValueAct has been holding shares of Twenty-First Century Fox Inc (NASDAQ:FOX) for some time now. As we discussed last summer, the investor purchased an $1.0 billion position, as Twenty-First Century Fox Inc (NASDAQ:FOX) had been in talks to acquire Time Warner (NYSE:TWX).

ValueAct is an activist fund that was co-founded by Jeff Ubben in 2000. Prior to ValueAct, Ubben was managing partner at Richard Blum’s Blum Capital Partners. Ubben holds an MBA from the J. L. Kellogg Graduate School of Management at Northwestern University and a B.A. from Duke University.

ValueAct has about $18 billion in assets under management. The fund likes to invest in companies and quietly make changes from the inside. The typical holding period can last anywhere up to three years. ValueAct recently played a part in Armstrong World Industries (NYSE:AWI)’s decision to split its flooring business and ceiling business. Its other investments include Valeant Pharmaceuticals Intl Inc (NYSE:VRX), Microsoft Corporation (NASDAQ:MSFT), and others. Click here to see Ubben’s other stock picks.

Disclosure: None

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!